Zenoble R D, Kemppainen R J
Department of Small Animal Surgery, College of Veterinary Medicine, Auburn University, AL 36849.
J Am Vet Med Assoc. 1987 Sep 15;191(6):685-8.
Three corticosteroid products (triamcinolone acetonide, fluocinonide, betamethasone valerate) and a control product composed of water, petrolatum, mineral oil, cetyl alcohol, steryl alcohol, sodium lauryl sulfate, cholesterol, and methylparaben each were applied topically to healthy dogs (5 dogs/product) once daily for 5 consecutive days. Plasma concentrations of immunoreactive adrenocorticotropic hormone (iACTH) and cortisol were determined before 1 microgram of ACTH/kg of body weight was given intravenously (pre-ACTH values) and cortisol was again measured 60 minutes after ACTH was given (post-ACTH values). Cortisol and iACTH concentrations were determined in each dog before, during, and after administration of the corticosteroid products. All 3 corticosteroids caused prompt and sustained pituitary-adrenocortical suppression. Compared with control applications, the application of corticosteroids resulted in significant reduction of plasma cortisol and iACTH concentrations by day 2 of treatment, and the lower concentrations continued to day 5. One week after the last application of the corticosteroids, plasma iACTH concentrations in the corticosteroid-treated dogs had returned to the range of values for the control dogs; however, pre- and post-ACTH cortisol concentrations remained suppressed in all corticosteroid-treated dogs. Two weeks after the last treatment, the pre-ACTH plasma cortisol concentrations of corticosteroid-treated dogs returned to those of the control dogs, but the post-ACTH plasma cortisol concentrations remained suppressed. By 3 weeks after the last treatment, post-ACTH plasma cortisol concentrations of dogs treated with triamcinolone acetonide had returned to the range of values for the control dogs, but remained suppressed in the other 2 groups of dogs. All indices of pituitary-adrenocortical activity were within the control range by 4 weeks after the last treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
三种皮质类固醇产品（曲安奈德、氟轻松、戊酸倍他米松）和一种由水、凡士林、矿物油、十六醇、硬脂醇、月桂醇硫酸酯钠、胆固醇和对羟基苯甲酸甲酯组成的对照产品，分别每天一次局部应用于健康犬（每种产品5只犬），连续应用5天。在静脉注射1微克促肾上腺皮质激素/千克体重之前（促肾上腺皮质激素前值）测定血浆免疫反应性促肾上腺皮质激素（iACTH）和皮质醇浓度，并在给予促肾上腺皮质激素60分钟后再次测量皮质醇（促肾上腺皮质激素后值）。在给予皮质类固醇产品之前、期间和之后，测定每只犬的皮质醇和iACTH浓度。所有三种皮质类固醇均引起垂体-肾上腺皮质的迅速和持续抑制。与对照应用相比，皮质类固醇的应用在治疗第2天时导致血浆皮质醇和iACTH浓度显著降低，且较低浓度持续至第5天。在最后一次应用皮质类固醇一周后，接受皮质类固醇治疗的犬的血浆iACTH浓度已恢复到对照犬的值范围；然而，所有接受皮质类固醇治疗的犬的促肾上腺皮质激素前和后皮质醇浓度仍受到抑制。在最后一次治疗两周后，接受皮质类固醇治疗的犬的促肾上腺皮质激素前血浆皮质醇浓度恢复到对照犬的水平，但促肾上腺皮质激素后血浆皮质醇浓度仍受到抑制。在最后一次治疗3周后，用曲安奈德治疗的犬的促肾上腺皮质激素后血浆皮质醇浓度已恢复到对照犬的值范围，但在其他两组犬中仍受到抑制。在最后一次治疗4周后，所有垂体-肾上腺皮质活动指标均在对照范围内。（摘要截短至250字）
